참고문헌
- Tarlatzis BC, Pados G. Oocyte donation: clinical and practical aspects. Molecular and Cellular Endocrinology 2000; 161: 99-102 https://doi.org/10.1016/S0303-7207(99)00229-4
- Borini A, Dal Prato L, Bianchi L, Violini F, Cattoli M, Flamigni C. Effect of duration of estradiol replacement on the outcome of oocyte donation. J Assist Reprod Genet 2001; 18: 185-90
- Paulson RJ, Hatch IE, Lobo RA, Sauer MV. Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. Hum Reprod 1997; 12: 835-9 https://doi.org/10.1093/humrep/12.4.835
- Soderstrom-Anttila V, Foudila T, Hovatta O. Oocyte donation in infertility treatment a review. Acta Obstet Gynecol Scand 2001; 80: 191-9 https://doi.org/10.1034/j.1600-0412.2001.080003191.x
- Hovatta O, Soderström-Anttila V, Foudila T, Tuomivaara L, Juntunen K, Tiitinen A, et al. Pregnancies after oocyte donation in women with ovarian failure caused by an inactivating mutation in the follicle stimulating hormone receptor. Hum Reprod 2002; 17: 124-7 https://doi.org/10.1093/humrep/17.1.124
- Khastgir G, Abdalla H, Thomas A, Korea L, Latarche L, Studd J. Oocyte donation in Turner's syndrome: an analysis of the factors affecting the outcome. Hum Reprod 1997; 12: 279-85 https://doi.org/10.1093/humrep/12.2.279
- Yaron Y, Ochshorn Y, Amit A, Kogosowski A, Yovel I, Lessing JB. Oocyte donation in Israel: a study of 1001 initiated treatment cycles. Hum Reprod 1998; 13: 1819-24 https://doi.org/10.1093/humrep/13.7.1819
- Remohi J, Yalil S, Gartner B, Simon C, Gallardo E, Pellicer A. Pregnancy and birth rates after oocyte donation. Fertil Steril 1997; 67: 717-23 https://doi.org/10.1016/S0015-0282(97)81372-6
- Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1998; 541: 259-62 https://doi.org/10.1111/j.1749-6632.1988.tb22263.x
- Felberbaum RE, Albano C, Ludwig M, Riethmüller-Winzen H, Grigat M, Devroey P, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000; 15: 1015-20 https://doi.org/10.1093/humrep/15.5.1015
-
The European and Middle East Orgalutran
${\(R)}$ Study Group. Comparable clinical outcome using the Gn RH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644-51 https://doi.org/10.1093/humrep/16.4.644 - Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874-85 https://doi.org/10.1093/humrep/17.4.874
- Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod 2001; 16: 1588-91 https://doi.org/10.1093/humrep/16.8.1588
- Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix(R) ) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13: 2411-4 https://doi.org/10.1093/humrep/13.9.2411
- Christin-Maitre S, Olivennes F, Dubourdieu S, Chabbert-Buffet N, Charbonnel B, Frydman R, et al. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation. Clin Endocrinol 2000; 52: 721-6 https://doi.org/10.1046/j.1365-2265.2000.00992.x
- Felberbaum R, Reissmann T, Kupker W, Al-Hasani S, Bauer O, Schill T, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet 1996; 13: 216-22 https://doi.org/10.1007/BF02065939
- Olivennes F, Ayoubi JM, Fanchin R, Rongières-Bertrand C, Hamamah S, Bouchard P, et al. GnRH antagonist in single-dose applications. Hum Reprod Update 2000; 6: 313-7 https://doi.org/10.1093/humupd/6.4.313
- Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Riethmuller-Winzen H, Reissmann T, et al. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, Cetrorelix, and GnRH agonists. Eur J Obstet Gyn Reprod Biol 2000; 93: 91-5 https://doi.org/10.1016/S0301-2115(99)00294-8
- Yaron Y, Amit A, Kogosowski A, Reuben Peyser M, David MP, Lessing JB. The optimal number of embryos to be transferred in shared oocyte donation: walking the thin line between low pregnancy rates and multiple pregnancies. Hum Reprod 1997; 12: 699-702 https://doi.org/10.1093/humrep/12.4.699
- Cohen MA, Lindheim SR, Sauer MV. Donor age is paramount to success in oocyte donation. Hum Reprod 1999; 14: 2755-8 https://doi.org/10.1093/humrep/14.11.2755
- Moomjy M, Cholst I, Mangieri R, Rosenwaks Z. Oocyte donation: insights into implantation. Fertil Steril 1999; 71: 15-21 https://doi.org/10.1016/S0015-0282(98)00420-8
- Prapas Y, Prapas N, Jones EE, Duleba AJ, Olive DL, Chatziparasidou A, et al. The window for embryo transfer in oocyte donation cycles depends on the duration of progesterone therapy. Hum Reprod 1998; 13: 720-3 https://doi.org/10.1093/humrep/13.3.720
- Sauer MV, Paulson RJ, Lobo RA. Comparing the clinical utility of GnRH antagonist to GnRH agonist in an oocyte donation program. Gynecol Obstet Invest 1997; 43: 215-8 https://doi.org/10.1159/000291860